novo nordisk glp-1 receptor agonist weight management diabetes treatments Novo's GLP-1/Amylin Dual Amycretin to Enter Late-Stage Trials for Obesity Nutritional priorities to support GLP-1
Description
National polls show up to one-fifth of American adults have tried GLP-1s for weight loss or to address health conditions, such as heart disease
ApoE -/- : apolipoprotein E-deficient
:max_bytes(150000):strip_icc()/GettyImages-16924367652-9ad3c91c6df34bc29f1c28f0b773d643.jpg)
Monitor for mild side effects such as nausea or appetite changes
Levy E, Delvin E, Marcil V, Spahis S
Over time, this can lead to insulin resistance , a precursor to type 2 diabetes
